A leader in the discovery of oral direct-acting antiviral therapies.

COVID-19 AND AT-527

AT-527 addresses the key challenges of the COVID-19 pandemic and beyond.

For the treatment of COVID-19, we need transformational solutions, and we believe that oral, safe, direct-acting antivirals can play an essential role worldwide. The value and global health impact of a direct-acting antiviral is to rapidly inhibit viral replication in the early phase of infection, which has the effect of reducing disease progression and curtailing the spread of infection.

While vaccines will play an important role in mitigating the COVID-19 pandemic, we will need treatment options to stay ahead of the virus. To treat patients who are waiting to or do not want to be immunized and for patients for whom the vaccine does not create protective immunity, direct-acting antivirals are and will remain an essential complement to vaccines.

AT-527 is an oral, direct-acting antiviral drug candidate.

AT-527 is being evaluated for easy and early administration to reduce burden and duration of disease. AT-527 has the potential to be used for pre- and post-exposure prophylaxis, to reduce transmission and to impact long-term COVID sequelae.